Effects of Ezetimibe on the Absorption of Oxidized Cholesterol

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

September 30, 2008

Conditions
Hypercholesterolemia
Interventions
DRUG

ezetimibe

Blinded study medication (ezetimibe 10 mg in tablet form) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.

DRUG

placebo

Blinded study medication (matched placebo) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.

Trial Locations (1)

94705

Cholesterol Research Center, Berkeley

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Merck Schering-Plough

UNKNOWN

lead

UCSF Benioff Children's Hospital Oakland

OTHER